139 related articles for article (PubMed ID: 3493074)
1. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. II. Lyt-1+2- T cells have potential to reject antigenically irrelevant (bystander) tumor cells on activation with the specific target tumor cells.
Yoshioka T; Fujiwara H; Takai Y; Ogata M; Shimizu J; Hamaoka T
Cancer Immunol Immunother; 1987; 24(1):8-12. PubMed ID: 3493074
[TBL] [Abstract][Full Text] [Related]
2. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
[TBL] [Abstract][Full Text] [Related]
3. Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells.
Sakamoto K; Fujiwara H; Nakajima H; Yoshioka T; Takai Y; Hamaoka T
Jpn J Cancer Res; 1986 Nov; 77(11):1142-52. PubMed ID: 3098724
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms for recognition of tumor antigens and mediation of anti-tumor effect by noncytolytic Lyt-2+ T cell subset.
Sakamoto K; Yoshioka T; Shimizu J; Sato S; Nakajima H; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1988 Jan; 79(1):99-108. PubMed ID: 3128511
[TBL] [Abstract][Full Text] [Related]
5. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.
Fujiwara H; Takai Y; Sakamoto K; Hamaoka T
J Immunol; 1985 Sep; 135(3):2187-91. PubMed ID: 3874911
[TBL] [Abstract][Full Text] [Related]
6. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
Tomita S; Fujiwara H; Yamane Y; Sano S; Nakajima H; Izumi Y; Arai H; Kawanishi Y; Tsuchida T; Hamaoka T
Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830
[TBL] [Abstract][Full Text] [Related]
7. The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo.
Yoshioka T; Fukuzawa M; Takai Y; Wakamiya N; Ueda S; Kato S; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1986; 21(3):193-8. PubMed ID: 2938736
[TBL] [Abstract][Full Text] [Related]
8. Effector cell analysis of tumor cell rejection in vivo in two syngeneic tumor systems exhibiting distinct in vitro cytotoxic mechanisms.
Fukuzawa M; Fujiwara H; Yoshioka T; Itoh K; Hamaoka T
Gan; 1984 Oct; 75(10):912-9. PubMed ID: 6334626
[TBL] [Abstract][Full Text] [Related]
9. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
[TBL] [Abstract][Full Text] [Related]
10. Studies on macrophage-activating factor (MAF) in antitumor immune responses. II. Molecular characterization of MAF produced by the tumor-immune Lyt-1+2- T cell subset.
Nakajima H; Izumi Y; Sugihara S; Satoh Y; Isumi S; Gotoh T; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1987; 25(3):201-8. PubMed ID: 3119213
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers.
Suda T; Fujiwara H; Mizushima Y; Shearer GM; Hamaoka T
J Natl Cancer Inst; 1986 Dec; 77(6):1267-72. PubMed ID: 2948049
[TBL] [Abstract][Full Text] [Related]
12. Enhanced induction of tumor-specific Lyt-1+2- T cell-mediated protective immunity by in vivo administration of interleukin 1.
Izumi Y; Tsuchida T; Okuno K; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1985 Sep; 76(9):863-70. PubMed ID: 3932286
[TBL] [Abstract][Full Text] [Related]
13. Differential ability of tumor-unique and cross-reactive antigen(s) on two murine hepatoma cell lines to induce Lyt-1+2- T cells responsible for in vivo protective immunity.
Shima J; Yoshioka T; Kosugi A; Ogata M; Fujiwara H; Hamaoka T; Ueda S; Kato S
Biken J; 1987 Mar; 30(1):1-8. PubMed ID: 2445335
[TBL] [Abstract][Full Text] [Related]
14. Mediation of in vivo tumor-neutralizing activity by Lyt-2+ as well as L3T4+ T cell subsets.
Yoshioka T; Sato S; Ogata M; Sakamoto K; Sano H; Shima J; Yamamoto H; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1988 Jan; 79(1):91-8. PubMed ID: 2965692
[TBL] [Abstract][Full Text] [Related]
15. Selective suppression of the generation of anti-tumor L3T4+ but not of Lyt-2+ T cell-mediated immunity in the tumor-bearing state.
Sano H; Sato S; Shima J; Tada T; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1988 Jul; 79(7):857-65. PubMed ID: 3139599
[TBL] [Abstract][Full Text] [Related]
16. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
[TBL] [Abstract][Full Text] [Related]
17. The activation of L3T4+ helper T cells assisting the generation of anti-tumor Lyt-2+ cytotoxic T lymphocytes: requirement of Ia-positive antigen-presenting cells for processing and presentation of tumor antigens.
Kosugi A; Yoshioka T; Suda T; Sano H; Takahama Y; Fujiwara H; Hamaoka T
J Leukoc Biol; 1987 Dec; 42(6):632-41. PubMed ID: 2960766
[TBL] [Abstract][Full Text] [Related]
18. Suppressive effect of portal venous inoculation with tumor cells on the anti-tumor immune potential.
Kokudo S; Qian JH; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1987 Sep; 78(9):946-51. PubMed ID: 3117751
[TBL] [Abstract][Full Text] [Related]
19. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
Barker E; Wise JA; Dray S; Mokyr MB
Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
[TBL] [Abstract][Full Text] [Related]
20. Additional evidence for the augmented induction of tumor-specific resistance in vaccinia virus-primed mice by immunization with vaccinia virus-modulated syngeneic tumor cells.
Ueda S; Wakamiya N; Wu KS; Kato S; Fujiwara H; Hamaoka T
Biken J; 1984 Mar; 27(1):1-7. PubMed ID: 6385960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
